Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.94 Analyst target: $4.00 Upside: 327.72%
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company is headquartered in Baltimore, Maryland.
See the full interactive analysis & chart →Informational only — not investment advice.